SCHEMBL4189065

SCHEMBL4189065

COc1ccc(CNc2cncc(-c3ccc(OC)c(OC)c3)c2)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
MAPT P10636 4/20 0.56
KDM4E B2RXH2 3/20 0.56
TDP1 Q9NUW8 3/20 0.56
GAA P10253 3/20 0.56
POLB P06746 2/20 0.56
KMT2A Q03164 2/20 0.53
LMNA P02545 2/20 0.53
HPGD P15428 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KCNH2 Q12809 1/20 0.51
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
RAB9A P51151 1/20 0.47
MEN1 O00255 1/20 0.47
PDE4B Q07343 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
DYRK1A Q13627 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4180512 0.90 KCNH2 (0.51) ALDH1A1MAPTKDM4ETDP1GAA
SCHEMBL4155473 0.90 ALDH1A1 (0.51) ALDH1A1MAPTKDM4ETDP1GAA
SCHEMBL4184437 0.90 ALPL (0.51) ALDH1A1MAPTKDM4ETDP1GAA
SCHEMBL4191630 0.90 ALDH1A1 (0.53) ALDH1A1MAPTKDM4ETDP1GAA
SCHEMBL4189975 0.87 FYN (0.55) ALDH1A1MAPTKDM4ETDP1GAA
SCHEMBL4189206 0.86 MAPT (0.58) ALDH1A1MAPTKDM4ETDP1POLB
SCHEMBL4187573 0.85 FYN (0.61) ALDH1A1MAPTKDM4ETDP1GAA
SCHEMBL4199417 0.83 BRAF (0.61) ALDH1A1MAPTGAAPOLBKMT2A
SCHEMBL4191971 0.83 HDAC1 (0.47) ALDH1A1MAPTKDM4ETDP1GAA
SCHEMBL4201192 0.81 PDGFRB (0.50) ALDH1A1MAPTKDM4EGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US claimed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP claimed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO claimed
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2020-07-02 US disclosed
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo BROWN DENNIS M (US) 2019-08-20 US disclosed
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2016-08-25 US disclosed
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US disclosed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP disclosed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo NEK9, NEK7, NEK3 ALDH1A1 2624/4885MAPT 3192/4885KDM4E 3218/4885
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 ALDH1A1 2624/4885MAPT 3192/4885KDM4E 3218/4885
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 ALDH1A1 2624/4885MAPT 3192/4885KDM4E 3218/4885
US-20090196912-A1 Pyridinylamines PRNP, PLPBP, SNCA ALDH1A1 1221/4885MAPT 23/4885KDM4E 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.